Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

A Randomized Phase 1 of of MZE001 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05249621
Recruitment Status : Completed
First Posted : February 21, 2022
Last Update Posted : February 6, 2023
Information provided by (Responsible Party):
Maze Therapeutics

Brief Summary:
This is a Phase 1, randomized, double-blind, placebo-controlled, single (SAD) / multiple (MAD) ascending dose and food effect study.

Condition or disease Intervention/treatment Phase
Healthy Drug: MZE001 Drug: Placebo Phase 1

Detailed Description:
Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered MZE001 in healthy subjects, in fasted and fed states. Each SAD and MAD cohort will enroll 8 subjects randomized 6 active: 2 placebo to receive single or multiple doses of MZE001.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 121 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of MZE001 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Actual Study Start Date : February 7, 2022
Actual Primary Completion Date : December 21, 2022
Actual Study Completion Date : December 21, 2022

Arm Intervention/treatment
Experimental: MZE001
MZE001 is a small molecule inhibitor of muscle glycogen synthase for the potential treatment of Pompe disease.
Drug: MZE001
Small molecule inhibitor of muscle glycogen synthase
Other Name: MZ1449348

Placebo Comparator: Placebo
Excipients containing no active ingredients.
Drug: Placebo
Product containing excipients with no active ingredients
Other Name: mannitol, silicified microcrystalline cellulose, magnesium stearate

Primary Outcome Measures :
  1. Number of participants with adverse events as a measure of safety and tolerability of MZE001 [ Time Frame: 14 days ]
    Occurrence of adverse events, serious adverse events, adverse events of special interest

Secondary Outcome Measures :
  1. Maximum concentration following multiple doses of MZE001 [ Time Frame: 14 days ]

  2. AUC following multiple doses of MZE001 [ Time Frame: 14 days ]

  3. Accumulation ratio following multiple doses of MZE001 [ Time Frame: 14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Male and female subjects, ages 18 - 55 years, inclusive;
  2. Must provide written informed consent prior to any study assessments and be willing and able to comply with all study procedures;
  3. Body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive;
  4. Healthy as determined by the Investigator based on pre-study medical history, physical examination, and baseline safety laboratory studies.
  5. Able to complete exercise treadmill test with no cardiac abnormalities detected
  6. Females of childbearing potential who are sexually active with a non-sterilized partner must use a highly effective method of contraception during study participation and for 30 days after last administration of study drug.
  7. Males of childbearing potential must use a highly effective method of birth control during study participation and for 90 days after last administration of study drug.

Exclusion Criteria:

  1. Any concurrent condition that in the opinion of the Investigator would interfere with the evaluation of the investigational product or lead to increased risk of harm;
  2. Any history of coronary artery disease or cardiovascular disease;
  3. History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs;
  4. History of cancer within past 5 years, with the exception of non-melanoma skin cancer and treated / excised melanoma;
  5. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to the Screening visit;
  6. Fridericia's corrected QT (QTcF) > 450 ms for male participants and > 470 ms for female participants or history of QT interval prolongation;
  7. History or presence of an abnormal ECG that is clinically significant in the Investigator's opinion
  8. Resting seated blood pressure < 90/40 mmHg or > 140/90 mmHg
  9. Resting seated heart rate < 45 bpm or > 99 bpm
  10. Poor peripheral venous access;
  11. Have a history of drug hypersensitivity or anaphylaxis;
  12. Current smoker or recent history of smoking within the last 3 months prior to the Screening visit;
  13. Have a history of alcoholism or drug abuse or positive drug screen
  14. Have used any prescription or non-prescription medicines or have been administered a vaccine within 14 days of admission,
  15. Have received any investigational drug within 30 days or < 5 half-lives, whichever is longer, prior to the Screening visit;
  16. Have donated or received any blood or blood products within the 3 months prior to the Screening visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05249621

Layout table for location information
United States, California
Orange County Research Center
Tustin, California, United States, 92780
Sponsors and Collaborators
Maze Therapeutics
Layout table for investigator information
Study Director: Sarah Noonberg, MD Maze Therapeutics
Layout table for additonal information
Responsible Party: Maze Therapeutics Identifier: NCT05249621    
Other Study ID Numbers: MZE001-01
First Posted: February 21, 2022    Key Record Dates
Last Update Posted: February 6, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diuretics, Osmotic
Natriuretic Agents
Physiological Effects of Drugs